Core Viewpoint - Tibet Pharmaceutical (600211.SH) reported a slight increase in revenue and net profit for the first half of 2025, emphasizing its commitment to investor returns through stable dividend policies [1][2]. Financial Performance - The company achieved operating revenue of 1.651 billion yuan, a year-on-year increase of 2.23% [1] - The net profit attributable to shareholders, after deducting non-recurring items, was 543 million yuan, reflecting a growth of 3.69% [1] - A cash dividend of 8.81 yuan per 10 shares (including tax) is proposed, totaling approximately 284 million yuan, which represents 50.05% of the net profit for the period [1] Product Performance - The main product, Xinhuasu, generated sales of approximately 1.456 billion yuan, accounting for about 88.36% of the main business revenue, with a slight increase in sales volume to around 4.17 million units [1] - Other products contributed approximately 192 million yuan in sales, marking a significant year-on-year growth of 18.83% [2] - The company’s product line focuses on cardiovascular diseases, with Xinhuasu, Yimuduo, and Nuodikan as key offerings [2] R&D and Market Position - Tibet Pharmaceutical benefits from unique ecological Tibetan medicinal resources, with Nuodikan being a notable product derived from Rhodiola rosea [2] - The company is actively advancing research on traditional Tibetan medicine and cultivating Tibetan medicinal herbs to support product diversification and sustainable development [2] - In March 2025, the company invested 300 million yuan in Jiangsu Chentai Pharmaceutical Technology Co., acquiring a 13.04% stake, and became the exclusive distributor for Zorifertinib in mainland China [3]

西藏药业表示，本报告期，营业收入与归属净利润变动比例不一致的主要原因系本报告期公司收到的产 业扶持款较上年同期减少8865万元，使本期净利同比减少8067万元。 北京商报讯（记者 丁宁）8月15日晚间，西藏药业（600211）披露半年报显示，公司上半年实现营业收 入16.51亿元，同比增长2.23%；归属净利润5.67亿元，同比下降8.96%。 ...

证券日报网讯 8月15日晚间，西藏药业发布公告称，公司第八届监事会第十次会议审议通过了《2025年 半年度报告全文及摘要》等多项议案。 （文章来源：证券日报） ...

Core Viewpoint - Tibet Pharmaceutical announced the approval of the full text and summary of the 2025 semi-annual report during the 10th meeting of the 8th Board of Directors [2] Group 1 - The company held its 10th meeting of the 8th Board of Directors on August 15 [2] - Multiple proposals were reviewed and approved during the meeting [2]

西藏药业2025半年报 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月15日，西藏药业发布公告称，2025年上半年实现营业 收入16.51亿元，同比增长2.23%；归属于上市公司股东的净利润为5.67亿元，同比下降8.96%；归属于 上市公司股东的扣除非经常性损益的净利润5.43亿元，同比增长3.69%。 ...

Group 1: Company Announcements - KWH Holdings announced that its controlling shareholder is planning to transfer shares, which may lead to a change in control. The stock will be suspended from trading for up to 2 days starting August 18, 2025 [2] - New Natural Gas announced that its overseas subsidiary, Zhongneng Holdings, plans to conduct a rights issue based on a 1-for-2 ratio, raising approximately HKD 239 million for project expenses. This will involve a capital restructuring that does not affect shareholder equity [3] - Lianhong New Science plans to absorb its wholly-owned subsidiary, Lianhong Chemical, to enhance management efficiency and reduce costs. This merger will not impact the company's financial status [4] Group 2: Financial Performance - Shengyi Electronics reported a 91% increase in revenue to CNY 3.769 billion and a 452% increase in net profit to CNY 531 million for the first half of 2025, proposing a cash dividend of CNY 0.3 per 10 shares [7] - Landun Optoelectronics experienced a 27.26% decline in revenue to CNY 186 million and a net loss of CNY 35.071 million in the first half of 2025, proposing a cash dividend of CNY 0.05 per 10 shares [9] - Tianjin Pharmaceutical reported a 1.91% decrease in revenue to CNY 4.288 billion but a 16.97% increase in net profit to CNY 775 million, proposing a cash dividend of CNY 2.1 per 10 shares [10] - Electric Science Digital's revenue increased by 7.56% to CNY 4.855 billion, but net profit fell by 19.33% to CNY 108 million, proposing a cash dividend of CNY 0.6 per 10 shares [11] - Tibet Pharmaceutical's revenue grew by 2.23% to CNY 1.651 billion, but net profit decreased by 8.96% to CNY 567 million, proposing a cash dividend of CNY 8.81 per 10 shares [12] - Jinwei Co. reported a 19.62% increase in net profit to CNY 253 million, proposing a cash dividend of CNY 2 per 10 shares [13] - Puyang Co. saw a 48.26% decline in net profit to CNY 68.903 million despite a 3.57% increase in revenue to CNY 2.794 billion [14] - Tongguan Copper Foil turned a profit with a net income of CNY 34.954 million, up from a loss, on revenue of CNY 2.997 billion, a 44.80% increase [15] - Jizhong Energy reported a 27.87% decline in revenue to CNY 7.293 billion and a 65.24% drop in net profit to CNY 348 million [16] - Botong Co. achieved a 42.95% increase in net profit to CNY 13.333 million, with revenue of CNY 149 million, a 5.23% increase [17] - Jinwo Co. reported a 94% increase in net profit to CNY 25.469 million, with revenue of CNY 614 million, a 7.96% increase [18] - Stone Technology's revenue increased by 78.96% to CNY 7.903 billion, but net profit fell by 39.55% to CNY 678 million [19] - North Car Blue Valley reported a revenue increase of 154.38% to CNY 9.517 billion but a net loss of CNY 2.308 billion [20] Group 3: Shareholder Actions - Shuyatong announced that its major shareholder plans to reduce its stake by up to 2% within three months [21] - Western Gold announced that a shareholder plans to reduce its stake by up to 1% [22] - Kang Enbei announced a plan to reduce its stake by up to 1% [23] - Changchun Yidong announced that a major shareholder plans to reduce its stake by up to 2.97% [24] Group 4: Financing and Contracts - Anshuo Information plans to raise up to CNY 600 million through a private placement for various projects [24] - China National Materials International signed an EPC contract for a cement production line in Saudi Arabia worth USD 298 million [25] - Yinlong Co. signed a labor subcontracting contract worth CNY 108 million [25] - *ST Songfa signed two procurement framework contracts for ship steel plates worth approximately CNY 3.371 billion [25]

智通财经APP讯，西藏药业(600211.SH)披露2025年半年度报告，报告期公司实现营收16.51亿元，同比 增长2.23%;归属于上市公司股东的净利润5.67亿元，同比下降8.96%;扣非净利润5.43亿元，同比增长 3.69%;基本每股收益1.76元。公司拟向全体股东每10股派发现金红利8.81元(含税)。 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-026 西藏诺迪康药业股份有限公司 关于取消监事会并修订《公司章程》及部分制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公司于 2025 年 8 月 14 日召开第八届监事会第十次会议审议通过了《关于取消监事 会的议案》；于同日召开的第八届董事会第十次会议审议通过了《关于取消监事会涉及修订 <公司章程>及配套制度的议案》、修订《董事会审计委员会实施细则》等制度的议案。具体 情况如下： 一、取消监事会 根据中国证监会《关于新公司法配套制度规则实施相关过渡期安排》，上市公司应当在 2026 年 1 月 1 日前，按照《公司法》及相关配套制度的规定，在《公司章程》中规定在董 事会中设审计委员会，行使《公司法》规定的监事会的职权，不再设监事会或者监事。公 司按照上述规定，结合《上市公司章程指引》（2025 年 3 月修订）《上海证券交易所股票上 市规则》（2025 年 4 月修订）等有关法律、法规、规范性文件，公司决定取消监事会，由 审计委员会行使《公司法 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-027 西藏诺迪康药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 2 日 14 点 30 分 召开地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 2 日 至2025 年 9 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召 股东大会召开日期：2025年9月2日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 开当日的交易时间 ...